SEC Filing Summary: AntriaBio, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 31, 2014, covers the completion of a private placement transaction (PIPE Financing) by AntriaBio, Inc. The filing details the "Subsequent Close" of the financing, which followed an "Initial Close" on December 4, 2014. The company is a Delaware corporation headquartered in Louisville, Colorado.
Key Financial Metrics
- Gross Cash Proceeds: $6.9 million (excluding placement agent compensation, transaction costs, fees, and expenses).
- Unit Price: $1.85 per Unit.
- Unit Composition: One share of common stock and one common share purchase warrant.
- Warrant Exercise Price: $2.50 per share.
- Warrant Term: 36 months from the Close date.
- Placement Agent Compensation: A Financing Warrant covering shares equal to 17.5% of the gross proceeds, exercisable at $2.50 per share for 7 years.
Material Changes
The primary material change is the capital raise of $6.9 million through the issuance of unregistered securities. This transaction increased the company's cash position and diluted existing shareholders through the issuance of new common stock and warrants. The filing notes that the securities were sold in reliance on exemptions under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D to accredited investors.
Outlook, Risks, and Contingencies
- Registration Rights: The Company agreed to file a registration statement within 90 days of the Close to cover the Offered Shares, Warrant Shares, and Financing Warrant Shares, keeping it effective until resale is permitted under Rule 144.
- Liquidity Risk: The securities issued in this transaction are unregistered and cannot be offered or sold in the United States absent registration or an applicable exemption.
- Dilution: The Financing Warrant includes cashless exercise rights and adjustments for stock splits or reorganizations.
- Regulatory Status: The filing includes a Rule 135C notice stating that the report does not constitute an offer to sell securities.
Investor Verification Checklist
- Verify the final number of Units issued and the total number of shares outstanding post-closing.
- Confirm the filing date and effectiveness of the Registration Statement required within 90 days of the Close.
- Review the specific terms of the Subscription Agreements (Exhibit 10.1) for any additional covenants or restrictions.
- Assess the impact of the 17.5% placement agent warrant on future dilution.
- Check for any subsequent press releases or filings regarding the use of the $6.9 million in proceeds.